Overview
Cyclic AMP, commonly known as cAMP, is an important intracellular second messenger that regulates a wide range of cellular responses. It is synthesized from ATP by the enzyme adenylate cyclase and plays a key role in signal transduction pathways activated by many hormones and neurotransmitters.
Cyclic AMP mediates the actions of hormones such as glucagon, adrenaline, ACTH, TSH, LH, FSH, ADH, and PTH by activating protein kinase A, which phosphorylates target proteins and alters cellular function. It also regulates ion channel activity, gene transcription, metabolism, smooth muscle relaxation, and water reabsorption in the kidneys. cAMP signaling is tightly controlled by phosphodiesterases, which degrade cAMP and terminate the signal.
Symptoms
Altered cAMP levels do not produce direct symptoms but manifest through hormonal and metabolic disturbances. Increased cAMP activity may be associated with symptoms of endocrine hyperfunction, such as weight loss, palpitations, excessive sweating, hypertension, muscle weakness, and metabolic imbalance.
Reduced cAMP response can present with hormone resistance syndromes, leading to fatigue, poor growth, hypocalcemia-related symptoms, polyuria, polydipsia, or impaired stress responses. Clinical features depend on the hormone pathway and target organ affected rather than cAMP itself.
Causes
Abnormal Cyclic AMP levels are caused by defects in hormone receptors, G proteins, adenylate cyclase activity, or phosphodiesterase function. Activating mutations of the Gs protein lead to constitutive cAMP production and are seen in conditions such as McCune–Albright syndrome and certain endocrine tumors.
Reduced Cyclic AMP generation occurs in hormone resistance states like pseudohypoparathyroidism due to impaired receptor or G protein signaling. Toxins such as cholera toxin and E. coli heat-labile toxin increase cAMP levels, leading to excessive intestinal secretion and diarrhea. Drugs that inhibit phosphodiesterases also increase intracellular cAMP.
Risk Factors
Risk factors for altered cAMP signaling include genetic mutations affecting G protein–coupled receptors or the GNAS gene, endocrine tumors, chronic hormonal disorders, and exposure to bacterial toxins.
Patients with renal disorders affecting ADH signaling, endocrine abnormalities, or inherited conditions such as Albright hereditary osteodystrophy are at higher risk. Use of drugs that modulate cAMP pathways, such as beta-agonists or phosphodiesterase inhibitors, can also influence cAMP levels.
Prevention
Prevention focuses on early identification and management of underlying hormonal and genetic disorders affecting cAMP signaling. Timely diagnosis of endocrine tumors and hormone resistance syndromes helps prevent complications related to abnormal cAMP activity.
Appropriate use and monitoring of drugs that alter cAMP levels reduce adverse effects. Proper sample collection, rapid processing, and correct storage are essential when measuring cAMP levels for diagnostic purposes. Early intervention and regular monitoring help maintain normal cellular signaling and metabolic balance.
